Chronic riluzole treatment increases glucose metabolism in rat prefrontal cortex and hippocampus

J Cereb Blood Flow Metab. 2008 Dec;28(12):1892-7. doi: 10.1038/jcbfm.2008.78. Epub 2008 Jul 16.

Abstract

Riluzole is believed to modulate glutamatergic function by reducing glutamate release and facilitating astroglial uptake. We measured (13)C labeling in metabolites in prefrontal cortex and hippocampus during a 10 mins infusion of [1-(13)C]glucose in urethane anesthetized rats treated with riluzole (21 days, 4 mg/kg per day, i.p.) or saline. Total and (13)C concentrations of metabolites were determined in extracts using (1)H-[(13)C] NMR spectroscopy. In prefrontal cortex (P<0.05) and hippocampus (P<0.05) riluzole increased (13)C labeling over saline in glutamate-C4 (to 112% and 130%), GABA-C2 (to 142% and 171%), and glutamine-C4 (to 118% and 233%) without affecting total metabolite levels (P>0.2). Our findings indicate that contrary to expectation chronic riluzole enhanced glucose oxidative metabolism and glutamate/glutamine cycling.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Amino Acids / metabolism
  • Animals
  • Behavior, Animal / drug effects
  • Blood Glucose / metabolism
  • Glucose / metabolism*
  • Hippocampus / drug effects*
  • Hippocampus / metabolism
  • Male
  • Neuroprotective Agents* / administration & dosage
  • Neuroprotective Agents* / pharmacokinetics
  • Neuroprotective Agents* / pharmacology
  • Prefrontal Cortex / drug effects*
  • Prefrontal Cortex / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Riluzole* / administration & dosage
  • Riluzole* / pharmacokinetics
  • Riluzole* / pharmacology
  • Time Factors

Substances

  • Amino Acids
  • Blood Glucose
  • Neuroprotective Agents
  • Riluzole
  • Glucose